The detection of antibodies against GP210 is a strong indicator of PBC, and antibody titers against its C-terminal peptide serve as a clinical parameter for monitoring the disease (Nakamura et al. 2005; Wang et al. 2023b). Here, NUP210 is linked to primary biliary cholangitis.